 |
0 Diseases |  |
1 Trial |
|
1 Trial |  |
27 News |  |
- || zagotenemab (LY3303560) / Eli Lilly
P2 data, Journal: Assessment of Efficacy and Safety of Zagotenemab: Results From PERISCOPE-ALZ, a Phase 2 Study in Early Symptomatic Alzheimer Disease. (Pubmed Central) - Feb 26, 2024
P2
In participants with early symptomatic AD, zagotenemab failed to achieve significant slowing of clinical disease progression compared with placebo. Imaging biomarker and plasma NfL findings did not show evidence of pharmacodynamic activity or disease modification.
- || (2/4) Are more studies needed? Semorinemab is the fourth anti-tau treatment to come and go, after zagotenemab, ABBV-8E12, and gosuranemab. These interventions lower tau, as designed. They just do not improve symptoms. (Twitter) - Jun 14, 2022
- zagotenemab (LY3303560) / Eli Lilly
PRE-RECORDED: ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF ZAGOTENEMAB: RESULTS FROM PERISCOPE-ALZ, A PHASE 2 STUDY IN EARLY SYMPTOMATIC ALZHEIMER’S DISEASE (ONSITE: 113) - Dec 17, 2021 - Abstract #ADPD2022ADPD_495;
P2
Conclusions In participants with early symptomatic AD, zagotenemab failed to achieve significant slowing of clinical disease progression. Imaging biomarker and NfL findings did not show evidence of pharmacodynamic activity or disease modification.
- || Aduhelm (aducanumab) / Eisai, Biogen, zagotenemab (LY3303560) / Eli Lilly
Review, Journal: Comparative Analysis of Aducanumab, Zagotenemab and Pioglitazone as Targeted Treatment Strategies for Alzheimer's Disease. (Pubmed Central) - Dec 13, 2021
These have shown mixed results so far and the next few years will be critical to elucidate and interpret their broad long-term protective effects. A concerted effort is required to understand and strengthen the translation of pre-clinical findings from these drugs to routine clinical practice.
- |||| zagotenemab (LY3303560) / Eli Lilly
Trial completion: A Study of LY3303560 in Participants With Early Symptomatic Alzheimer's Disease (clinicaltrials.gov) - Nov 30, 2021
P2, N=360, Completed, Sponsor: Eli Lilly and Company
A concerted effort is required to understand and strengthen the translation of pre-clinical findings from these drugs to routine clinical practice. Active, not recruiting --> Completed
- zagotenemab (LY3303560) / Eli Lilly
[VIRTUAL] Novel use of tau imaging to enrich for pathological homogeneity within the PERISCOPE-ALZ study of zagotenemab () - Aug 2, 2021 - Abstract #AAIC2021AAIC_1940;
P2
As tau-targeted therapies for AD advance into clinical research, staged tau pathology as eligibility criterion may be useful in phase 2 proof-of-concept trials to test disease modifying therapies. Topline trial results are anticipated in late 2021.
- || donepezil / Generic mfg., galantamine hydrobromide / Generic mfg., memantine / Generic mfg.
Review, Journal: Alzheimer's disease: Recent treatment strategies. (Pubmed Central) - May 15, 2021
Current treatment for AD (donepezil, galantamine, rivastigmine and memantine) is only symptomatic and has modest benefits...Even the positive findings presented by Biogen on Aducanumab are not entirely clear and further data is necessary to confirm its validity...Four monoclonal antibodies anti-tau (Gosuranemab, Tilavonemab, Semorinemab and Zagotenemab) and one anti-tau vaccine (AADvac1) have reached phase II, so far. In this review, we discuss the potential disease-modifying agents tested in clinical trials and update the information of drugs that are still under clinical evaluation.
- [VIRTUAL] KEY BASELINE CHARACTERISTICS OF PARTICIPANTS ENROLLED USING TAU PET SCREENING IN TWO PHASE 2 TRIALS () - Aug 10, 2020 - Abstract #CTAD2020CTAD_92;
P2
TRAILBLAZER-ALZ phase 2 therapeutic trial with anti-N3pG antibody donanemab (LY3002813; NCT03367403) and PERISCOPE-ALZ phase 2 therapeutic trial with anti-tau antibody zagotenemab (LY3303560; NCT03518073) implemented National Institute about clinical trial participation and experiences with the US on Aging and Alzheimer’s Association (NIA-AA) guidelines for AD classification based on biomarker-defined pathological stage (Jack et al, Alzheimer’s and Dementia, 2018, 14, 535- 562) with a focus on identifying an early symptomatic AD population. Our findings provide initial insight on using tau PET-quantification to address AD clinical trial population pathologic and clinical heterogeneity.
- |||| zagotenemab (LY3303560) / Eli Lilly
Enrollment open: A Study of LY3303560 in Participants With Early Symptomatic Alzheimer's Disease (clinicaltrials.gov) - Jun 5, 2020
P2, N=285, Recruiting, Sponsor: Eli Lilly and Company
Our findings provide initial insight on using tau PET-quantification to address AD clinical trial population pathologic and clinical heterogeneity. Active, not recruiting --> Recruiting
- | zagotenemab (LY3303560) / Eli Lilly
Enrollment closed: A Study of LY3303560 in Participants With Early Symptomatic Alzheimer's Disease (clinicaltrials.gov) - Sep 3, 2019
P2, N=285, Active, not recruiting, Sponsor: Eli Lilly and Company
Active, not recruiting --> Recruiting Recruiting --> Active, not recruiting
- | zagotenemab (LY3303560) / Eli Lilly
Trial primary completion date: A Study of LY3303560 in Participants With Early Symptomatic Alzheimer's Disease (clinicaltrials.gov) - Aug 19, 2019
P2, N=285, Recruiting, Sponsor: Eli Lilly and Company
Recruiting --> Active, not recruiting Trial primary completion date: Jan 2021 --> Aug 2021
- || zagotenemab (LY3303560) / Eli Lilly
Trial completion, Trial completion date: A Study of LY3303560 in Participants With Mild Cognitive Impairment or Alzheimer's Disease (clinicaltrials.gov) - Jul 5, 2019
P1, N=24, Completed, Sponsor: Eli Lilly and Company
Trial primary completion date: Jan 2021 --> Aug 2021 Active, not recruiting --> Completed | Trial completion date: Jun 2020 --> Jun 2019
- | zagotenemab (LY3303560) / Eli Lilly
Trial completion: A Study of LY3303560 in Healthy Participants and Participants With Alzheimer's Disease (AD) (clinicaltrials.gov) - Jul 23, 2018
P1, N=110, Completed, Sponsor: Eli Lilly and Company
Active, not recruiting --> Completed | Trial completion date: Jun 2020 --> Jun 2019 Active, not recruiting --> Completed
- | zagotenemab (LY3303560) / Eli Lilly
Trial completion date: A Study of LY3303560 in Participants With Mild Cognitive Impairment or Alzheimer's Disease (clinicaltrials.gov) - Jul 9, 2018
P1, N=24, Active, not recruiting, Sponsor: Eli Lilly and Company
Active, not recruiting --> Completed Trial completion date: Jun 2019 --> Jun 2020
- || zagotenemab (LY3303560) / Eli Lilly
Enrollment closed: A Study of LY3303560 in Participants With Mild Cognitive Impairment or Alzheimer's Disease (clinicaltrials.gov) - Jun 11, 2018
P1, N=24, Active, not recruiting, Sponsor: Eli Lilly and Company
Trial completion date: Jun 2019 --> Jun 2020 Recruiting --> Active, not recruiting
- ||||| zagotenemab (LY3303560) / Eli Lilly
New P2 trial: A Study of LY3303560 in Participants With Early Symptomatic Alzheimer's Disease (clinicaltrials.gov) - May 8, 2018
P2, N=285, Recruiting, Sponsor: Eli Lilly and Company
- zagotenemab (LY3303560) / Eli Lilly
Trial completion date, Trial primary completion date: A Study of LY3303560 in Participants With Mild Cognitive Impairment or Alzheimer's Disease (clinicaltrials.gov) - Mar 3, 2018
P1, N=24, Recruiting, Sponsor: Eli Lilly and Company
Recruiting --> Active, not recruiting Trial completion date: May 2019 --> Jun 2019 | Trial primary completion date: May 2019 --> Jun 2019
- zagotenemab (LY3303560) / Eli Lilly
Enrollment change, Trial primary completion date: A Study of LY3303560 in Participants With Mild Cognitive Impairment or Alzheimer's Disease (clinicaltrials.gov) - Feb 14, 2018
P1, N=24, Recruiting, Sponsor: Eli Lilly and Company
Trial completion date: May 2019 --> Jun 2019 | Trial primary completion date: May 2019 --> Jun 2019 N=132 --> 24 | Trial primary completion date: Feb 2020 --> May 2019
- || zagotenemab (LY3303560) / Eli Lilly
Enrollment closed, Trial completion date, Trial primary completion date: A Study of LY3303560 in Healthy Participants and Participants With Alzheimer's Disease (AD) (clinicaltrials.gov) - Feb 5, 2018
P1, N=110, Active, not recruiting, Sponsor: Eli Lilly and Company
N=132 --> 24 | Trial primary completion date: Feb 2020 --> May 2019 Recruiting --> Active, not recruiting | Trial completion date: May 2018 --> Jul 2018 | Trial primary completion date: May 2018 --> Jul 2018
- || zagotenemab (LY3303560) / Eli Lilly
Trial primary completion date: A Study of LY3303560 in Healthy Participants and Participants With Alzheimer's Disease (AD) (clinicaltrials.gov) - Sep 1, 2017
P1, N=110, Recruiting, Sponsor: Eli Lilly and Company
Recruiting --> Active, not recruiting | Trial completion date: May 2018 --> Jul 2018 | Trial primary completion date: May 2018 --> Jul 2018 Trial primary completion date: May 2019 --> Apr 2018
- || zagotenemab (LY3303560) / Eli Lilly
Trial primary completion date: A Study of LY3303560 in Participants With Mild Cognitive Impairment or Alzheimer's Disease (clinicaltrials.gov) - Sep 1, 2017
P1, N=132, Recruiting, Sponsor: Eli Lilly and Company
Trial primary completion date: May 2019 --> Apr 2018 Trial primary completion date: May 2020 --> Feb 2020
- || zagotenemab (LY3303560) / Eli Lilly
Enrollment change: A Study of LY3303560 in Healthy Participants and Participants With Alzheimer's Disease (AD) (clinicaltrials.gov) - Aug 3, 2017
P1, N=110, Recruiting, Sponsor: Eli Lilly and Company
Trial primary completion date: May 2020 --> Feb 2020 N=90 --> 110
- || zagotenemab (LY3303560) / Eli Lilly
Trial primary completion date: A Study of LY3303560 in Healthy Participants and Participants With Alzheimer's Disease (AD) (clinicaltrials.gov) - Jul 11, 2017
P1, N=90, Recruiting, Sponsor: Eli Lilly and Company
N=90 --> 110 Trial primary completion date: May 2018 --> May 2019
- || zagotenemab (LY3303560) / Eli Lilly
Trial primary completion date: A Study of LY3303560 in Healthy Participants and Participants With Alzheimer's Disease (AD) (clinicaltrials.gov) - Jun 21, 2017
P1, N=90, Recruiting, Sponsor: Eli Lilly and Company
Trial primary completion date: May 2018 --> May 2019 Trial primary completion date: May 2017 --> May 2018
- || zagotenemab (LY3303560) / Eli Lilly
Trial primary completion date: A Study of LY3303560 in Participants With Mild Cognitive Impairment or Alzheimer's Disease (clinicaltrials.gov) - Mar 21, 2017
P1, N=132, Recruiting, Sponsor: Eli Lilly and Company
Trial primary completion date: May 2017 --> May 2018 Trial primary completion date: Nov 2018 --> Apr 2020
- || zagotenemab (LY3303560) / Eli Lilly
Trial primary completion date: A Study of LY3303560 in Participants With Mild Cognitive Impairment or Alzheimer's Disease (clinicaltrials.gov) - Feb 10, 2017
P1, N=132, Recruiting, Sponsor: Eli Lilly and Company
Trial primary completion date: Nov 2018 --> Apr 2020 Trial primary completion date: May 2018 --> Nov 2018
- ||| zagotenemab (LY3303560) / Eli Lilly
Enrollment open: A Study of LY3303560 in Participants With Mild Cognitive Impairment or Alzheimer's Disease (clinicaltrials.gov) - Feb 10, 2017
P1, N=132, Recruiting, Sponsor: Eli Lilly and Company
Trial primary completion date: May 2018 --> Nov 2018 Not yet recruiting --> Recruiting
- ||| zagotenemab (LY3303560) / Eli Lilly
New P1 trial: A Study of LY3303560 in Participants With Mild Cognitive Impairment or Alzheimer's Disease (clinicaltrials.gov) - Jan 12, 2017
P1, N=132, Not yet recruiting, Sponsor: Eli Lilly and Company
- ||| zagotenemab (LY3303560) / Eli Lilly
Enrollment open: A Study of LY3303560 in Healthy Participants and Participants With Alzheimer's Disease (AD) (clinicaltrials.gov) - May 27, 2016
P1, N=90, Recruiting, Sponsor: Eli Lilly and Company
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||| zagotenemab (LY3303560) / Eli Lilly
New P1 trial: A Study of LY3303560 in Healthy Participants and Participants With Alzheimer's Disease (AD) (clinicaltrials.gov) - Apr 28, 2016
P1, N=90, Not yet recruiting, Sponsor: Eli Lilly and Company